Søgeord (vaccination) valgt.
384 emner vises.
1
Danske børn bliver i høj grad vaccineret
Statens Serum Institut, 22.04.2024
Tilføjet 22.04.2024
Ny rapport viser, at tilslutningen til det danske børnevaccinationsprogram fortsat er høj og stabil, men der er stadig lidt at hente, før vi lever helt op til målsætningerne for alle vacciner. HPV-vaccinen har den laveste tilslutning blandt børnevaccinerne.
Læs mere
2
Increased reports of measles in the Metropolitan City of Milan, northern Italy, September 2023 to March 2024
Maria Gori, Clara Fappani, Silvia Bianchi, Sabrina Senatore, Daniela Colzani, Priscilla Pasutto, Melissa Baggieri, Silvia Gioacchini, Antonella Marchi, Paola Bucci, Emilio D’Ugo, Marino Faccini, Danilo Cereda, Luigi Vezzosi, Elisabetta Tanzi, Fabio Magurano and Antonella Amendola
Eurosurveillance latest updates, 19.04.2024
Tilføjet 19.04.2024
Since late 2023, the Metropolitan City of Milan and surrounding areas (northern Italy) have been experiencing a resurgence of measles, with most cases detected starting from January 2024. During this brief period, we observed measles in travellers from endemic areas, participants in international events, vaccinees and healthcare workers. Indigenous cases have also been identified. Even though we have not yet identified large and disruptive outbreaks, strengthening surveillance and vaccination activities is pivotal to help limit the impact of measles spread.
Læs mere
3
COVID-19 Vaccination Coverage, and Rates of SARS-CoV-2 Infection and COVID-19-Associated Hospitalization Among Residents in Nursing Homes - National Healthcare Safety Network, United States, October 2023-February 2024
Morbidity and Mortality Weekly Report (MMWR), 19.04.2024
Tilføjet 19.04.2024
This report describes COVID-19 rates, hospitalizations, and vaccination coverage among nursing home residents.
Læs mere
4
COVID Vaccinations Less Prevalent in Marginalized Patients
Medscape Infectious Diseases, 15.04.2024
Tilføjet 15.04.2024
Primary care doctors who serve marginalized communities had the highest rate of patients unvaccinated against COVID-19 in a recent study. Medscape Medical News
Læs mere
5
COVID-19 Vaccination Coverage - World Health Organization African Region, 2021-2023
Morbidity and Mortality Weekly Report (MMWR), 12.04.2024
Tilføjet 12.04.2024
This report describes COVID-19 vaccination coverage in the World Health Organization African Region during 2021-2023.
Læs mere
6
Interim analysis of COVID-19 vaccine effectiveness against hospitalisation due to COVID-19 and death using electronic health records in eight European countries: first update
ECDC
ECDC COVID-19 updates, 8.04.2024
Tilføjet 8.04.2024
This report presents pooled COVID-19 vaccine effectiveness (VE) estimates for the first, second and third booster doses (compared to complete primary vaccination with no booster) against hospitalisation due to COVID-19 and COVID-19-related death in resident populations ≥50 years of age living in the community.
Læs mere
7
Pertussis epidemic in Denmark, August 2023 to February 2024
Anne Christine Nordholm, Hanne-Dorthe Emborg, Sarah Kristine Nørgaard, Ulrikka Nygaard, Aoife Ronayne, Lise Birk Nielsen, Bolette Søborg, Peter H Andersen and Tine Dalby
Eurosurveillance latest updates, 5.04.2024
Tilføjet 5.04.2024
We report a record high pertussis epidemic in Denmark since August 2023. Highest incidence was in adolescents, while peak incidence in infants was lower vs previous epidemics in 2019 and 2016. Among infants aged 0–2 months, over half (29/48) were hospitalised and one infant died, underlining the disease severity in the youngest. To protect infants, pertussis vaccination in pregnant women was introduced in January 2024 in the national vaccination programme. Improved vaccination surveillance in pregnant women is being implemented.
Læs mere
8
Federal Retail Pharmacy Program Contributions to Bivalent mRNA COVID-19 Vaccinations Across Sociodemographic Characteristics - United States, September 1, 2022-September 30, 2023
Morbidity and Mortality Weekly Report (MMWR), 5.04.2024
Tilføjet 5.04.2024
This report describes the number of COVID-19 bivalent vaccine doses administered by Federal Retail Pharmacy Program partners.
Læs mere
9
COVID-19 vaccine effectiveness against symptomatic infection with SARS-CoV-2 BA.1/BA.2 lineages among adults and adolescents in a multicentre primary care study, Europe, December 2021 to June 2022
Charlotte Lanièce Delaunay, Iván Martínez-Baz, Noémie Sève, Lisa Domegan, Clara Mazagatos, Silke Buda, Adam Meijer, Irina Kislaya, Catalina Pascu, AnnaSara Carnahan, Beatrix Oroszi, Maja Ilić, Marine Maurel, Aryse Melo, Virginia Sandonis Martín, Camino Trobajo-Sanmartín, Vincent Enouf, Adele McKenna, Gloria Pérez-Gimeno, Luise Goerlitz, Marit de Lange, Ana Paula Rodrigues, Mihaela Lazar, Neus Latorre-Margalef, Gergő Túri, Jesús Castilla, Alessandra Falchi, Charlene Bennett, Virtudes Gallardo, Ralf Dürrwald, Dirk Eggink, Raquel Guiomar, Rodica Popescu, Maximilian Riess, Judit Krisztina Horváth, Itziar Casado, Mª del Carmen García, Mariëtte Hooiveld, Ausenda Machado, Sabrina Bacci, Marlena Kaczmarek, Esther Kissling and on behalf of the European Primary Care Vaccine Effectiveness Group
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundScarce European data in early 2021 suggested lower vaccine effectiveness (VE) against SARS-CoV-2 Omicron lineages than previous variants. AimWe aimed to estimate primary series (PS) and first booster VE against symptomatic BA.1/BA.2 infection and investigate potential biases. MethodsThis European test-negative multicentre study tested primary care patients with acute respiratory symptoms for SARS-CoV-2 in the BA.1/BA.2-dominant period. We estimated PS and booster VE among adults and adolescents (PS only) for all products combined and for Comirnaty alone, by time since vaccination, age and chronic condition. We investigated potential bias due to correlation between COVID-19 and influenza vaccination and explored effect modification and confounding by prior SARS-CoV-2 infection. ResultsAmong adults, PS VE was 37% (95% CI: 24–47%) overall and 60% (95% CI: 44–72%), 43% (95% CI: 26–55%) and 29% (95% CI: 13–43%)
Læs mere
10
Digital Nudges Found to Be Duds in Flu Vax Trial
Medscape Infectious Diseases, 28.03.2024
Tilføjet 28.03.2024
Reminders sent via text message or patient portal did not increase rates of influenza vaccination. Medscape Medical News
Læs mere
11
Getting Reluctant Patients to 'Yes' on COVID Vaccination
Medscape Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
Five useful tips for helping the vax-hesitant people get past their objections. Medscape Medical News
Læs mere
12
'Critical' to Catch Up on Measles Vaccinations to Stem Outbreaks, Says WHO
Medscape Infectious Diseases, 20.03.2024
Tilføjet 20.03.2024
Vaccinating children who missed their measles shots during the COVID-19 pandemic is critical, a senior World Health Organization official said on Tuesday, as outbreaks of... Reuters Health Information
Læs mere
13
US CDC Urges Measles Vaccinations Amid Rising Cases
Medscape Infectious Diseases, 19.03.2024
Tilføjet 19.03.2024
The U.S. Centers for Disease Control and Prevention (CDC) on Monday issued a health advisory urging people, particularly children and international travelers, to get... Reuters Health Information
Læs mere
14
Decoding Variants and Virology With Professor Marc Van Ranst
Medscape Infectious Diseases, 19.03.2024
Tilføjet 19.03.2024
Learn from Prof Van Ranst about SARS-CoV-2 with insights on varied immune effects, systemic implications, evolving variants, and their influence on vaccination and healthcare practices. Medscape Medical Affairs
Læs mere
15
Measles Control So Far in 2024: 'Not Off to a Great Start'
Medscape Infectious Diseases, 16.03.2024
Tilføjet 16.03.2024
The recent rise in cases across the country is linked to unvaccinated travelers and lower-than-ideal vaccination rates, experts said. WebMD Health News
Læs mere
16
Timing the New Meningitis Shots Serogroup Top 5's
Medscape Infectious Diseases, 14.03.2024
Tilføjet 14.03.2024
Clinicians are evaluating optimal timing for vaccination now that the first pentavalent vaccine against all five major serogroups of meningococcal disease is available. Medscape Medical News
Læs mere
17
Projecting COVID-19 intensive care admissions for policy advice, the Netherlands, February 2020 to January 2021
Don Klinkenberg, Jantien Backer, Nicolette de Keizer and Jacco Wallinga
Eurosurveillance latest updates, 8.03.2024
Tilføjet 8.03.2024
BackgroundModel projections of coronavirus disease 2019 (COVID-19) incidence help policymakers about decisions to implement or lift control measures. During the pandemic, policymakers in the Netherlands were informed on a weekly basis with short-term projections of COVID-19 intensive care unit (ICU) admissions. AimWe aimed at developing a model on ICU admissions and updating a procedure for informing policymakers. MethodThe projections were produced using an age-structured transmission model. A consistent, incremental update procedure integrating all new surveillance and hospital data was conducted weekly. First, up-to-date estimates for most parameter values were obtained through re-analysis of all data sources. Then, estimates were made for changes in the age-specific contact rates in response to policy changes. Finally, a piecewise constant transmission rate was estimated by fitting the model to reported daily ICU admissions, with a changepoint analysis guided by Akaike\'s Information Criterion. ResultsThe model and update procedure allowed us to make weekly projections. Most 3-week prediction intervals were accurate in covering the later observed numbers of ICU admissions. When projections were too high in March and August 2020 or too low in November 2020, the estimated effectiveness of the policy changes was adequately adapted in the changepoint analysis based on the natural accumulation of incoming data. ConclusionThe model incorporates basic epidemiological principles and most model parameters were estimated per data source. Therefore, it had potential to be adapted to a more complex epidemiological situation with the rise of new variants and the start of vaccination.
Læs mere
18
Effectiveness of Omicron XBB.1.5 vaccine against infection with SARS-CoV-2 Omicron XBB and JN.1 variants, prospective cohort study, the Netherlands, October 2023 to January 2024
Anne J Huiberts, Christina E Hoeve, Brechje de Gier, Jeroen Cremer, Bas van der Veer, Hester E de Melker, Janneke HHM van de Wijgert, Susan van den Hof, Dirk Eggink and Mirjam J Knol
Eurosurveillance latest updates, 8.03.2024
Tilføjet 8.03.2024
We estimated vaccine effectiveness (VE) of SARS-CoV-2 Omicron XBB.1.5 vaccination against self-reported infection between 9 October 2023 and 9 January 2024 in 23,895 XBB.1.5 vaccine-eligible adults who had previously received at least one booster. VE was 41% (95% CI: 23–55) in 18–59-year-olds and 50% (95% CI: 44–56) in 60–85-year-olds. Sequencing data suggest lower protection against the BA.2.86 (including JN.1) variant from recent prior infection (OR = 2.8; 95% CI:1.2–6.5) and, not statistically significant, from XBB.1.5 vaccination (OR = 1.5; 95% CI:0.8–2.6).
Læs mere
19
Effectiveness of interventions to increase healthcare workers’ adherence to vaccination against vaccine-preventable diseases: a systematic review and meta-analysis, 1993 to 2022
Marco Clari, Beatrice Albanesi, Rosanna Irene Comoretto, Alessio Conti, Erika Renzi, Michela Luciani, Davide Ausili, Azzurra Massimi and Valerio Dimonte
Eurosurveillance latest updates, 1.03.2024
Tilføjet 1.03.2024
BackgroundVaccination adherence among healthcare workers (HCWs) is fundamental for the prevention of vaccine-preventable diseases (VPDs) in healthcare. This safeguards HCWs\' well-being, prevents transmission of infections to vulnerable patients and contributes to public health. AimThis systematic review and meta-analysis aimed to describe interventions meant to increase HCWs’ adherence to vaccination and estimate the effectiveness of these interventions. MethodsWe searched literature in eight databases and performed manual searches in relevant journals and the reference lists of retrieved articles. The study population included any HCW with potential occupational exposure to VPDs. We included experimental and quasi-experimental studies presenting interventions aimed at increasing HCWs’ adherence to vaccination against VPDs. The post-intervention vaccination adherence rate was set as the main outcome. We included the effect of interventions in the random-effects and subgroup meta-analyses. ResultsThe systematic review considered 48 studies on influenza and Tdap vaccination from database and manual searches, and 43 were meta-analysed. A statistically significant, positive effect was seen in multi-component interventions in randomised controlled trials (relative risk (RR) = 1.37; 95% CI: 1.13–1.66) and in observational studies (RR = 1.43; 95% CI: 1.29–1.58). Vaccination adherence rate was higher in community care facilities (RR = 1.58; 95% CI: 1.49–1.68) than in hospitals (RR = 1.24; 95% CI: 0.76-2.05). ConclusionInterventions aimed at increasing HCWs’ adherence to vaccination against VPDs are effective, especially multi-component ones. Future research should determine the most effective framework of interventions for each setting, using appropriate study design for their evaluation, and should compare intervention components to understand their contribution to the effectiveness.
Læs mere
20
Burden of chickenpox complications in Poland, 2006 to 2021: A comprehensive registry-based study
Rafał Halik, Iwona Paradowska-Stankiewicz, Aneta Trochonowicz and Swavik Dittmer
Eurosurveillance latest updates, 1.03.2024
Tilføjet 1.03.2024
BackgroundChickenpox, a vaccine-preventable disease caused by the varicella zoster virus, generally presents with mild symptoms but can cause complications necessitating hospitalisation. In Poland, since 2009, vaccination has been obligatory for children up to 12 years of age who are particularly vulnerable to infection and for children in their vicinity. AimTo examine the burden of chickenpox complications and the trends of hospitalisation arising from these complications over time in the Polish population. MethodsData spanning 2006–21 were sourced from the Polish Infectious Diseases Surveillance System, the Nationwide General Hospital Morbidity Study and the Statistics Poland death registry. Standardised and age-specific incidence rates, hospital discharge rates and number of deaths because of chickenpox were calculated. Moreover, the joinpoint regression model was used to analyse trends of annual hospital discharge rates. ResultsOver the analysed timeframe, 25,804 hospitalisations and 52 deaths attributable to chickenpox complications were documented, and 1.0% of chickenpox cases required hospitalisation because of chickenpox. Age-standardised hospitalisation rates varied between 2.3 and 9.6 per 100,000 population. The analysis revealed no statistically significant trend in overall hospital discharge rates from chickenpox complications. However, a notable increase in hospitalisation rates was observed in children aged 0–4 and among inhabitants of rural areas, with annual percentage changes of 4.9% and 3.4% respectively. ConclusionsOur findings suggest that the implementation of a universal chickenpox immunisation programme, supported by health education, should be considered to reduce the number of hospitalisations and nearly eliminate deaths because of chickenpox.
Læs mere
21
Ongoing measles outbreak, the Federation of Bosnia and Herzegovina, December 2023 to February 2024
Sanjin Musa, Irma Salimović-Bešić, Jasmina Brkić Džambić, Nijaz Tihić, Anisa Bajramović, Suzana Arapčić, Amela Dedeić-Ljubović and Siniša Skočibušić
Eurosurveillance latest updates, 1.03.2024
Tilføjet 1.03.2024
We report on an ongoing measles outbreak in the Federation of Bosnia and Herzegovina with 141 cases notified between week 52 2023 and week 6 2024. Among those with known vaccination status, 97% were unvaccinated and the most affected group is children under the age of 5 years (n = 87) who were not vaccinated during the pandemic years. Sixty-eight cases were hospitalised, the most common complications were measles-related pneumonia and diarrhoea. The sequenced measles viruses from four cases belonged to genotype D8.
Læs mere
22
Britain Seeks 'urgent Reversal' Of Fall in Childhood Vaccination Rates
Medscape Infectious Diseases, 29.02.2024
Tilføjet 29.02.2024
Britain will on Thursday launch a drive to boost childhood vaccination rates, health authorities said, seeking an \'urgent reversal\' to a fall in uptake as the country faces... Reuters Health Information
Læs mere
23
Studie med 99 mio. deltagere: Alvorlige bivirkninger efter covid-19 vacciner er sjældne
Statens Serum Institut, 23.02.2024
Tilføjet 23.02.2024
Verdens største studie af covid-19 vaccinernes sikkerhed bekræfter, at alvorlige bivirkninger efter vaccination sjældne.
Læs mere
24
Measuring waning protection from seasonal influenza vaccination during nine influenza seasons, Ontario, Canada, 2010/11 to 2018/19
Hannah Chung, Michael A Campitelli, Sarah A Buchan, Aaron Campigotto, Natasha S Crowcroft, Jonathan B Gubbay, James KH Jung, Timothy Karnauchow, Kevin Katz, Allison J McGeer, J Dayre McNally, David C Richardson, Susan E Richardson, Laura C Rosella, Margaret L Russell, Kevin L Schwartz, Andrew Simor, Marek Smieja, Maria E Sundaram, Bryna F Warshawsky, George Zahariadis, Jeffrey C Kwong and on behalf of the Canadian Immunization Research Network (CIRN) Provincial Collaborative Network (PCN) Investigators
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWaning immunity from seasonal influenza vaccination can cause suboptimal protection during peak influenza activity. However, vaccine effectiveness studies assessing waning immunity using vaccinated and unvaccinated individuals are subject to biases. AimWe examined the association between time since vaccination and laboratory-confirmed influenza to assess the change in influenza vaccine protection over time. MethodsUsing linked laboratory and health administrative databases in Ontario, Canada, we identified community-dwelling individuals aged ≥ 6 months who received an influenza vaccine before being tested for influenza by RT-PCR during the 2010/11 to 2018/19 influenza seasons. We estimated the adjusted odds ratio (aOR) for laboratory-confirmed influenza by time since vaccination (categorised into intervals) and for every 28 days. ResultsThere were 53,065 individuals who were vaccinated before testing for influenza, with 10,264 (19%) influenza-positive cases. The odds of influenza increased from 1.05 (95% CI: 0.91–1.22) at 42–69 days after vaccination and peaked at 1.27 (95% CI: 1.04–1.55) at 126–153 days when compared with the reference interval (14–41 days). This corresponded to 1.09-times increased odds of influenza every 28 days (aOR = 1.09; 95% CI: 1.04–1.15). Individuals aged 18–64 years showed the greatest decline in protection against influenza A(H1N1) (aORper 28 days = 1.26; 95% CI: 0.97–1.64), whereas for individuals aged ≥ 65 years, it was against influenza A(H3N2) (aORper 28 days = 1.20; 95% CI: 1.08–1.33). We did not observe evidence of waning vaccine protection for individuals aged
Læs mere
25
Wastewater-based reproduction numbers and projections of COVID-19 cases in three areas in Japan, November 2021 to December 2022
Shogo Miyazawa, Ting Sam Wong, Genta Ito, Ryo Iwamoto, Kozo Watanabe, Michiel van Boven, Jacco Wallinga and Fuminari Miura
Eurosurveillance latest updates, 23.02.2024
Tilføjet 23.02.2024
BackgroundWastewater surveillance has expanded globally as a means to monitor spread of infectious diseases. An inherent challenge is substantial noise and bias in wastewater data because of the sampling and quantification process, limiting the applicability of wastewater surveillance as a monitoring tool. AimTo present an analytical framework for capturing the growth trend of circulating infections from wastewater data and conducting scenario analyses to guide policy decisions. MethodsWe developed a mathematical model for translating the observed SARS-CoV-2 viral load in wastewater into effective reproduction numbers. We used an extended Kalman filter to infer underlying transmissions by smoothing out observational noise. We also illustrated the impact of different countermeasures such as expanded vaccinations and non-pharmaceutical interventions on the projected number of cases using three study areas in Japan during 2021–22 as an example. ResultsObserved notified cases were matched with the range of cases estimated by our approach with wastewater data only, across different study areas and virus quantification methods, especially when the disease prevalence was high. Estimated reproduction numbers derived from wastewater data were consistent with notification-based reproduction numbers. Our projections showed that a 10–20% increase in vaccination coverage or a 10% reduction in contact rate may suffice to initiate a declining trend in study areas. ConclusionOur study demonstrates how wastewater data can be used to track reproduction numbers and perform scenario modelling to inform policy decisions. The proposed framework complements conventional clinical surveillance, especially when reliable and timely epidemiological data are not available.
Læs mere
26
Data on COVID-19 vaccination in the EU/EEA
ECDC
ECDC COVID-19 updates, 2.02.2024
Tilføjet 2.02.2024
This downloadable data file contains information on COVID-19 vaccination in the EU/EEA since September 2023.
Læs mere
27
Vaccination coverage in the EU/EEA during Autumn 2023 campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
Nearly 20 million people aged 60 years and above received COVID-19 vaccines during the autumn / winter campaign in the EU/EEA
Læs mere
28
Interim COVID-19 vaccination coverage in the EU/EEA during the 2023–24 season campaigns
ECDC
ECDC COVID-19 updates, 26.01.2024
Tilføjet 26.01.2024
This report presents an interim description of COVID-19 vaccine coverage in the European Union/European Economic Area (EU/EEA) between 1 September 2023 and January 2024.
Læs mere
29
South America Dengue Spike Prompts Vaccination Drive as Bug Spray Runs Out
Medscape Infectious Diseases, 26.01.2024
Tilføjet 26.01.2024
South America is seeing a surge in cases of the mosquito-borne disease dengue during the southern hemisphere summer, prompting Brazil to roll out a novel vaccine campaign,... Reuters Health Information
Læs mere
30
Allergivaccinationer har effekt i fem år
Statens Serum Institut, 25.01.2024
Tilføjet 25.01.2024
Det har tidligere været ukendt, hvor lang tid allergivaccinationer holder, men Statens Serum Institut har nu fundet ud af, at effekten varer i fem år.
Læs mere
31
Effectiveness of the adapted bivalent mRNA COVID-19 vaccines against hospitalisation in individuals aged ≥ 60 years during the Omicron XBB lineage-predominant period: VEBIS SARI VE network, Europe, February to August, 2023
Liliana Antunes, Clara Mazagatos, Iván Martínez-Baz, Verónica Gomez, Maria-Louise Borg, Goranka Petrović, Róisín Duffy, François E Dufrasne, Ralf Dürrwald, Mihaela Lazar, Ligita Jancoriene, Beatrix Oroszi, Petr Husa, Jennifer Howard, Aryse Melo, Francisco Pozo, Gloria Pérez-Gimeno, Jesús Castilla, Ausenda Machado, Aušra Džiugytė, Svjetlana Karabuva, Margaret Fitzgerald, Sébastien Fierens, Kristin Tolksdorf, Silvia-Odette Popovici, Auksė Mickienė, Gergő Túri, Lenka Součková, Nathalie Nicolay, Angela MC Rose and on behalf of the European Hospital Vaccine Effectiveness Group
Eurosurveillance latest updates, 19.01.2024
Tilføjet 19.01.2024
We conducted a multicentre hospital-based test-negative case–control study to measure the effectiveness of adapted bivalent COVID-19 mRNA vaccines against PCR-confirmed SARS-CoV-2 infection during the Omicron XBB lineage-predominant period in patients aged ≥ 60 years with severe acute respiratory infection from five countries in Europe. Bivalent vaccines provided short-term additional protection compared with those vaccinated > 6 months before the campaign: from 80% (95% CI: 50 to 94) for 14–89 days post-vaccination, 15% (95% CI: −12 to 35) at 90–179 days, and lower to no effect thereafter.
Læs mere
32
Seroprevalence of tick-borne encephalitis virus and vaccination coverage of tick-borne encephalitis, Sweden, 2018 to 2019
Bo Albinsson, Tove Hoffman, Linda Kolstad, Tomas Bergström, Gordana Bogdanovic, Anna Heydecke, Mirja Hägg, Torbjörn Kjerstadius, Ylva Lindroth, Annika Petersson, Marie Stenberg, Sirkka Vene, Patrik Ellström, Bengt Rönnberg and Åke Lundkvist
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
BackgroundIn Sweden, information on seroprevalence of tick-borne encephalitis virus (TBEV) in the population, including vaccination coverage and infection, is scattered. This is largely due to the absence of a national tick-borne encephalitis (TBE) vaccination registry, scarcity of previous serological studies and use of serological methods not distinguishing between antibodies induced by vaccination and infection. Furthermore, the number of notified TBE cases in Sweden has continued to increase in recent years despite increased vaccination. AimThe aim was to estimate the TBEV seroprevalence in Sweden. MethodsIn 2018 and 2019, 2,700 serum samples from blood donors in nine Swedish regions were analysed using a serological method that can distinguish antibodies induced by vaccination from antibodies elicited by infection. The regions were chosen to reflect differences in notified TBE incidence. ResultsThe overall seroprevalence varied from 9.7% (95% confidence interval (CI): 6.6–13.6%) to 64.0% (95% CI: 58.3–69.4%) between regions. The proportion of vaccinated individuals ranged from 8.7% (95% CI: 5.8–12.6) to 57.0% (95% CI: 51.2–62.6) and of infected from 1.0% (95% CI: 0.2–3.0) to 7.0% (95% CI: 4.5–10.7). Thus, more than 160,000 and 1,600,000 individuals could have been infected by TBEV and vaccinated against TBE, respectively. The mean manifestation index was 3.1%. ConclusionA difference was observed between low- and high-incidence TBE regions, on the overall TBEV seroprevalence and when separated into vaccinated and infected individuals. The estimated incidence and manifestation index argue that a large proportion of TBEV infections are not diagnosed.
Læs mere
33
Early influenza vaccine effectiveness estimates using routinely collected data, Alberta, Canada, 2023/24 season
Christa Smolarchuk, Carla Ickert, Nathan Zelyas, Jeffrey C Kwong and Sarah A Buchan
Eurosurveillance latest updates, 12.01.2024
Tilføjet 12.01.2024
Timely and precise influenza vaccine effectiveness (VE) estimates are needed to guide public health messaging and impact vaccine uptake immediately. Using routinely collected laboratory, vaccination and health administrative data from Alberta, Canada, we estimated influenza VE against infection for the 2023/24 season on a near real-time basis, to late December, at 61% (95% CI: 58–64) against influenza A(H1N1), 49% (95% CI: 28–63) against influenza A(H3N2) and 75% (95% CI: 58–85) against influenza B.
Læs mere
34
Relative vaccine effectiveness against COVID-19 hospitalisation in persons aged ≥ 65 years: results from a VEBIS network, Europe, October 2021 to July 2023
Mario Fontán-Vela, Esther Kissling, Nathalie Nicolay, Toon Braeye, Izaak Van Evercooren, Christian Holm Hansen, Hanne-Dorthe Emborg, Massimo Fabiani, Alberto Mateo-Urdiales, Ala'a AlKerwi, Susanne Schmitz, Jesús Castilla, Iván Martínez-Baz, Brechje de Gier, Susan Hahné, Hinta Meijerink, Jostein Starrfelt, Baltazar Nunes, Constantino Caetano, Tarik Derrough, Anthony Nardone, Susana Monge and VEBIS-Lot4 working group
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
To monitor relative vaccine effectiveness (rVE) against COVID-19-related hospitalisation of the first, second and third COVID-19 booster (vs complete primary vaccination), we performed monthly Cox regression models using retrospective cohorts constructed from electronic health registries in eight European countries, October 2021–July 2023. Within 12 weeks of administration, each booster showed high rVE (≥ 70% for second and third boosters). However, as of July 2023, most of the relative benefit has waned, particularly in persons ≥ 80-years-old, while some protection remained in 65–79-year-olds.
Læs mere
35
Early COVID-19 vaccine effectiveness of XBB.1.5 vaccine against hospitalisation and admission to intensive care, the Netherlands, 9 October to 5 December 2023
C Henri van Werkhoven, Anne-Wil Valk, Bente Smagge, Hester E de Melker, Mirjam J Knol, Susan JM Hahné, Susan van den Hof and Brechje de Gier
Eurosurveillance latest updates, 5.01.2024
Tilføjet 5.01.2024
We present early vaccine effectiveness (VE) estimates of the 2023 seasonal COVID-19 XBB.1.5 vaccine against COVID-19 hospitalisation and admission to an intensive care unit (ICU) in previously vaccinated adults ≥ 60 years in the Netherlands. We compared vaccination status of 2,050 hospitalisations including 92 ICU admissions with age group-, sex-, region- and date-specific population vaccination coverage between 9 October and 5 December 2023. VE against hospitalisation was 70.7% (95% CI: 66.6–74.3), VE against ICU admission was 73.3% (95% CI: 42.2–87.6).
Læs mere
36
Influenza, Updated COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes influenza, updated COVID-19, and respiratory syncytial virus vaccination coverage among adults.
Læs mere
37
Coverage with Influenza, Respiratory Syncytial Virus, and Updated COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, December 2023
Morbidity and Mortality Weekly Report (MMWR), 21.12.2023
Tilføjet 21.12.2023
This report describes respiratory syncytial virus, influenza, and COVID-19 vaccination coverage among nursing home residents.
Læs mere
38
Skin manifestations after immunisation with an adjuvanted recombinant zoster vaccine, Germany, 2020
Stefano Orru', Sibylle Bierbaum, Alexander Enk, Hartmut Hengel, Marcus Hoffelner, Daniela Huzly, Brigitte Keller-Stanislawski, Vera Mahler, Maja Mockenhaupt and Doris Oberle
Eurosurveillance latest updates, 15.12.2023
Tilføjet 15.12.2023
BackgroundShortly after the launch of a novel adjuvanted recombinant zoster vaccine (RZV), Shingrix, cases of suspected herpes zoster (HZ) or zoster-like skin reactions following immunisation were reported. AimWe aimed to investigate if these skin manifestations after administration of RZV could be HZ. MethodsBetween April and October 2020, general practitioners (GP) reporting a suspected case of HZ or zoster-like skin manifestation after RZV vaccination to the Paul-Ehrlich-Institut, the German national competent authority, were invited to participate in the study. The GP took a sample of the skin manifestation, photographed it and collected patient information on RZV vaccination and the suspected adverse event. We analysed all samples by PCR for varicella-zoster virus (VZV) and herpes-simplex virus (HSV) and genotyped VZV-positive samples. In addition, cases were independently assessed by two dermatologists. ResultsEighty eligible cases were enrolled and 72 could be included in the analysis. Of the 72 cases, 45 were female, 33 were 60–69 years old, 32 had skin symptoms in the thoracic and 27 in the cervical dermatomes. Twenty-seven samples tested PCR positive for VZV (all genotyped as wild-type, WT), three for HSV-1 and five for HSV-2. ConclusionIt may be difficult to distinguish HZ, without a PCR result, from other zoster-like manifestations. In this study, VZV-PCR positive dermatomal eruptions occurring in the first weeks after immunisation with RZV were due to WT VZV, which is not unexpected as HZ is a common disease against which the vaccine is unlikely to provide full protection at this time.
Læs mere
39
Factors associated with parental intention to vaccinate their child against influenza, Finland, February to March, 2022: a web-based survey
Idil Hussein, Simopekka Vänskä, Jonas Sivelä, Tuija Leino and Hanna Nohynek
Eurosurveillance latest updates, 8.12.2023
Tilføjet 8.12.2023
BackgroundInfluenza vaccination for children aged 6 months to 6 years is included in the national vaccination programme in Finland. Although all vaccines in the programme are free of charge, national coverage of influenza vaccination among children under 3 years and 3–6 years during 2020/21 was 43% and 35% respectively, with regional differences. AimTo assess factors underlying parental vaccination intention in order to increase influenza vaccine uptake among children. MethodsWe conducted a web-based survey among parents (n = 17,844) of randomly selected eligible children (aged 6 months–6 years) in February–March 2022 in five Finnish municipalities from regions of high and low coverage. Logistic regressions were used to determine associations between vaccination intention and e.g. sociodemographic factors, attitudes and knowledge. Linkage to the national vaccination register was used to confirm realisation of vaccination intention after the study. ResultsParticipation rate was 13% (n = 2,322 parents). Influenza knowledge, trust in official information, responding parent’s education level, adherence to the vaccination programme, number of children and changes in attitudes towards vaccination since COVID-19 were all associated with intention to vaccinate. Vaccination intention for children was 64%, and realised vaccination 51%. ConclusionDespite the low participation rate, both vaccinated and unvaccinated children were represented. Influenza vaccine uptake is not dependent on a single factor. Our results identified the need for open dialogue between parents and healthcare professionals, as the lack of vaccine being offered by healthcare professionals was the most reported reason for not vaccinating.
Læs mere
40
COVID Vaccines Likely Reversed Premature Birth Trend
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Researchers suggest this provides further evidence of benefit of SARS-CoV-2 vaccination before or during pregnancy. Medscape Medical News
Læs mere
41
QuickStats: Age-Adjusted Percentage of Adults Aged ≥18 Years Who Received an Influenza Vaccination During the Past 12 Months, by Sex and Race and Ethnicity - National Health Interview Survey, United States, 2022
Morbidity and Mortality Weekly Report (MMWR), 1.12.2023
Tilføjet 1.12.2023
This report describes the percentage of adults who received a flu vaccine during the past 12 months.
Læs mere
42
Global Measles Deaths Increased by 43% in 2022
Medscape Infectious Diseases, 28.11.2023
Tilføjet 28.11.2023
The rise in measles outbreaks and deaths is not surprising, given the recent decline in vaccination rates, said an official of the US Centers for Disease Control and Prevention. Medscape Medical News
Læs mere
43
Extra Messages About HPV Shots Boost Vaccination Rates
Medscape Infectious Diseases, 28.11.2023
Tilføjet 28.11.2023
Children whose parents received a reminder notification that their child was due for vaccination against human papillomavirus were 56% more likely to get the potentially lifesaving shot. WebMD Health News
Læs mere
44
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, F Annabel Niessen, Ausenda Machado, Odile Launay, Sarah Denayer, Lucie Seyler, Joaquin Baruch, Cristina Burgui, Isabela I Loghin, Lisa Domegan, Roberta Vaikutytė, Petr Husa, George Panagiotakopoulos, Nassera Aouali, Ralf Dürrwald, Jennifer Howard, Francisco Pozo, Bartolomé Sastre-Palou, Diana Nonković, Mirjam J Knol, Irina Kislaya, Liem binh Luong Nguyen, Nathalie Bossuyt, Thomas Demuyser, Aušra Džiugytė, Iván Martínez-Baz, Corneliu Popescu, Róisín Duffy, Monika Kuliešė, Lenka Součková, Stella Michelaki, Marc Simon, Janine Reiche, María Teresa Otero-Barrós, Zvjezdana Lovrić Makarić, Patricia CJL Bruijning-Verhagen, Verónica Gomez, Zineb Lesieur, Cyril Barbezange, Els Van Nedervelde, Maria-Louise Borg, Jesús Castilla, Mihaela Lazar, Joan O’Donnell, Indrė Jonikaitė, Regina Demlová, Marina Amerali, Gil Wirtz, Kristin Tolksdorf, Marta Valenciano, Sabrina Bacci, Esther Kissling, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March–June)- and Delta (June–December)-dominant periods, 2021. MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case–control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset. ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69–92) overall and 75% (95% CI: 42–90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18–74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57–98). In time-since-vaccination analysis, complete all-product PSV VE was > 90% in those with their last dose
Læs mere
45
Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Omicron-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021 to 2022
Angela MC Rose, Nathalie Nicolay, Virginia Sandonis Martín, Clara Mazagatos, Goranka Petrović, Joaquin Baruch, Sarah Denayer, Lucie Seyler, Lisa Domegan, Odile Launay, Ausenda Machado, Cristina Burgui, Roberta Vaikutyte, F Annabel Niessen, Isabela I Loghin, Petr Husa, Nassera Aouali, George Panagiotakopoulos, Kristin Tolksdorf, Judit Krisztina Horváth, Jennifer Howard, Francisco Pozo, Virtudes Gallardo, Diana Nonković, Aušra Džiugytė, Nathalie Bossuyt, Thomas Demuyser, Róisín Duffy, Liem binh Luong Nguyen, Irina Kislaya, Iván Martínez-Baz, Giedre Gefenaite, Mirjam J Knol, Corneliu Popescu, Lenka Součková, Marc Simon, Stella Michelaki, Janine Reiche, Annamária Ferenczi, Concepción Delgado-Sanz, Zvjezdana Lovrić Makarić, John Paul Cauchi, Cyril Barbezange, Els Van Nedervelde, Joan O’Donnell, Christine Durier, Raquel Guiomar, Jesús Castilla, Indrė Jonikaite, Patricia CJL Bruijning-Verhagen, Mihaela Lazar, Regina Demlová, Gil Wirtz, Marina Amerali, Ralf Dürrwald, Mihály Pál Kunstár, Esther Kissling, Sabrina Bacci, Marta Valenciano, I-MOVE-COVID-19 hospital study team and VEBIS hospital study team
Eurosurveillance latest updates, 24.11.2023
Tilføjet 24.11.2023
IntroductionThe I-MOVE-COVID-19 and VEBIS hospital networks have been measuring COVID-19 vaccine effectiveness (VE) in participating European countries since early 2021. AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in patients ≥ 20 years hospitalised with severe acute respiratory infection (SARI) from December 2021 to July 2022 (Omicron-dominant period). MethodsIn both networks, 46 hospitals (13 countries) follow a similar test-negative case–control protocol. We defined complete primary series vaccination (PSV) and first booster dose vaccination as last dose of either vaccine received ≥ 14 days before symptom onset (stratifying first booster into received
Læs mere
46
Notes from the Field: House-to-House Campaign Administration of Inactivated Poliovirus Vaccine - Sokoto State, Nigeria, November 2022
Morbidity and Mortality Weekly Report (MMWR), 23.11.2023
Tilføjet 23.11.2023
This report describes results of a house-to-house poliovirus vaccination campaign in Nigeria.
Læs mere
47
Can physicians and schools mitigate social inequalities in human papillomavirus vaccine awareness, uptake and vaccination intention among adolescents? A cross-sectional study, France, 2021 to 2022
Hadrien Moffroid, Damien Oudin Doglioni, Sandra Chyderiotis, Jonathan Sicsic, Anne-Sophie Barret, Jocelyn Raude, Sebastien Bruel, Aurelie Gauchet, Morgane Michel, Amandine Gagneux-Brunon, Nathalie Thilly, Judith E Mueller and on behalf of the PrevHPV Consortium
Eurosurveillance latest updates, 17.11.2023
Tilføjet 17.11.2023
BackgroundIn France, human papillomavirus (HPV) vaccination coverage varies across socioeconomic levels. AimWe aimed at assessing HPV vaccine awareness, uptake and vaccination intention among adolescents in France. MethodsIn a cluster-randomised study, 13–15-year-old students in 61 French middle schools completed a web-based questionnaire. We used multivariable logistic regression to evaluate determinants of HPV vaccine awareness, self-reported uptake and vaccination intention among unvaccinated students and interaction terms to explore effects of visits to family physician and remembering school lessons on vaccination. The French deprivation index of school municipalities served as proxy for socioeconomic levels. ResultsAmong 6,992 participants, awareness was significantly associated with parental education (odds ratio (OR) = 0.82; 95% confidence interval (CI): 0.71–0.95), language spoken at home (OR = 0.59; 95% CI: 0.52–0.66) and deprivation level (OR = 0.57; 95% CI: 0.44–0.71), regardless of physician visit or school lessons. Vaccine uptake was associated with parental education without a recent physician visit (OR = 0.31; 95% CI: 0.16–0.59, vs OR = 0.64; 95% CI: 0.52–0.78 with a visit, interaction p = 0.045). Vaccination intention among unvaccinated was associated with deprivation level (moderate-low vs low) among students not remembering school lessons on vaccination (OR = 0.17; 95% CI: 0.05-0.62, vs OR = 0.93; 95% CI: 0.51–1.67 remembering school lessons, interaction p = 0.022). Parental education was associated with vaccination intention among students reporting a physician visit (OR = 0.41; 95% CI: 0.26–0.64 vs OR = 1.05; 95% CI: 0.50–2.20 without a visit, interaction p = 0.034). ConclusionOur results suggest that healthcare and school could promote vaccination and mitigate social inequalities in HPV vaccination coverage.
Læs mere
48
Declines in Influenza Vaccination Coverage Among Health Care Personnel in Acute Care Hospitals During the COVID-19 Pandemic - United States, 2017-2023
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes declines in influenza vaccination coverage among health care personnel working in hospitals during the COVID-19 pandemic.
Læs mere
49
Influenza and Up-to-Date COVID-19 Vaccination Coverage Among Health Care Personnel - National Healthcare Safety Network, United States, 2022-23 Influenza Season
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes the percentage of health care personnel working in hospitals and nursing homes who received a flu vaccine and the percentage who received a COVID-19 vaccine.
Læs mere
50
Coverage with Selected Vaccines and Exemption from School Vaccine Requirements Among Children in Kindergarten - United States, 2022-23 School Year
Morbidity and Mortality Weekly Report (MMWR), 9.11.2023
Tilføjet 9.11.2023
This report describes vaccination coverage and changes in exemption from school vaccine requirements among kindergartners.
Læs mere